B O O K - American College of Rheumatology

More documents

Recommendations

Info

ACR/ARHP Poster Session C 256 1764. Novel Multiplex Technology for Diagnostic Characterization of Rheumatoid Arthritis. Piyanka E. Chandra 4 , Jeremy Sokolove 3 , Berthold G. Hipp 1 , Heike Eberl 1 , Ursula Klause 1 and William Robinson 2 , 1 Roche Diagnostics, 2 Stanford Univ School of Med, Stanford, CA, 3 Stanford University, Mountain View, CA, 4 Stanford University. 1765. Patient Questionnaire Scores for Physical Function and Pain Are More Likely Than Erythrocyte Sedimentation Rate (ESR) To Document a Quantitative Abnormality in New Patients with Rheumatoid Arthritis (RA). Theodore Pincus 1 and Christopher J. Swearingen 2 , 1 New York University Hospital for Joint Disease, Hastings-on-Hudson, NY, 2 University of Arkansas for Medical Sciences, Little Rock, AR. 1766. Preliminary Rheumatoid Arthritis (RA) Flare Assessment for Randomized Clinical Trials (RCTs): An Outcome Measures in Rheumatology (OMERACT) Data-Driven, Patient-Centered, and Consensus-Based Initiative. Clifton O. Bingham 3 , Ernest Choy 4 , Rieke Alten 6 , Maarten Boers 11 , Peter Brooks 9 , Vivian Bykerk 1 , Robin Christensen 5 , Dan Furst 8 , Sarah Hewlett 10 , Amye Leong 2 , James May, Christof Pohl 6 , Tessa Sanderson 10 , Vibeke Strand 7 and Thasia Woodworth, 1 Brigham and Women’s, 2 Healthy Motivation, 3 Johns Hopkins University, Baltimore, MD, 4 King’s College, 5 Parker Institute: Musculoskeletal Statistics Unit Copenhagen University Hospital, 6 Schlosspark Klinik University Charite, 7 Stanford University, 8 UCLA, 9 University of Queensland, 10 University of the West of England, 11 Vu University Medical Center. 1767. Preliminary Validation for the Short Version of the Valued Life Activities Questionnaire (S-VLA). Afton L. Hassett 5 , Diane C. Radvanski 3 , Anagha Nadkarni 1 , Steven Buyske 2 , Sam A. Schiff 3 , Moti L. Tiku 3 and Patricia P. Katz 4 , 1 Bristol-Myers Squibb Co, Princeton, NJ, 2 Rutgers University, New Brunswick, NJ, 3 UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 4 University of California, San Francisco, CA, 5 University of Michigan Medical School, Ann Arbor, MI. 1768. Presence and Predictors of Poor Functional Outcomes in US Hispanics with Rheumatoid Arthritis (RA). George A. Karpouzas 4 , Soha Dolatabadi 1 , Rosalinda C. Moran 3 , Perry Nicassio 5 and Michael H. Weisman 2 , 1 Cedars Sinai, Los Angeles, CA, 2 Cedars-Sinai Medical Center, Los Angeles, CA, 3 Harbor UCLA, Carson, CA, 4 Harbor-UCLA, Long Beach, CA, 5 UCLA. 1769. Progression Patterns of Radiographic Damage: Results from SONORA Study. Maggie Chen 1 , Xiuying Li 1 , Pooneh Akhavan 2 and Claire Bombardier 3 , 1 University Health Network, 2 University of Toronto, University Health Network, 3 University of Toronto, University Health Network, Mount Sinai Hospital, Toronto, ON, Canada. 1770. Quantification of Periarticular Osteopenia in Rheumatoid Arthritis. Inhye E. Ahn 3 , Ji Hyeon Ju 1 , Kwi Young Kang 2 , Seung-Ki Kwok 1 , Kyung-su Park 1 , Sung-Hwan Park 1 and Ho- Youn Kim 1 , 1 Department of Internal Medicine, Division of Rheumatology, Catholic University of Korea, Seoul, Korea, Republic of, 2 Department of Internal Medicine, Division of Rheumatology, Chungbuk University, Cheongju, Korea, Republic of, 3 Department of Internal Medicine, The Methodist Hospital, Houston, TX. 1771. Radiological Progression in Very Early Rheumatoid Arthritis, Results of the DREAM Remission Induction Cohort. Marloes Vermeer 3 , Ina H. Kuper 3 , Monique Hoekstra 1 , Hein J. Bernelot Moens 4 , Piet L. C. M. van Riel 2 and Mart A. F. J. van de Laar 3 , 1 Isala Klinieken, Zwolle, The Netherlands, 2 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 3 University of Twente and Medisch Spectrum Twente, Enschede, The Netherlands, 4 Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands. 2010 Program Book 1772. Retinal Vascular Caliber Is Altered in Patients with Rheumatoid Arthritis: A Biomarker of Disease Activity and Cardiovascular Risk? Sharon Van Doornum 3 , Gemma Strickland 2 , Ryo Kawasaki 3 , Jing Xie 3 , Lauren Hodgson 3 , Ian Wicks 1 and Tien Wong 3 , 1 Royal Melbourne Hospital, Melbourne, Australia, 2 Royal Melbourne Hospital, 3 University of Melbourne. 1773. Serum Undercarboxylated Osteocalcin Levels in Patients with Rheumatoid Arthritis. Kuninobu Wakabayashi, Kumiko Otsuka, Michihito Sato, Ryo Takahashi, Tsuyoshi Odai, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. 1774. The 2010 ACR/EULAR Criteria for Rheumatoid Arthritis Perform Well in Prediction of Clinical RA Diagnosis at 6 Months in Very Early Arthritis Patients: Longitudinal Data from the NOR-VEAC Cohort. Maria D. Mjaavatten 3 , Desiree M. Van Der Heijde 8 , Till Uhlig 5 , Anne J. Haugen 1 , Halvor Nygaard 6 , Olav Bjørneboe 9 , Nils G. Arvidson 7 , Hans C. Gulseth 2 and Tore K. Kvien 4 , 1 Østfold Hospital, Moss, Norway, 2 Betanien Hospital, Skien, Norway, 3 Diakonhjemmet Hospital, Oslo, Norway, 4 Diakonhjemmet Hospital, Oslo, Norway, 5 Diakonhjemmet Hospital, Oslo, Norway, 6 Hospital for Rheumatic Diseases, Lillehammer, Norway, 7 Innlandet Hospital, Kongsvinger, Norway, 8 Leiden University Medical Center, Meerssen, The Netherlands, 9 Martina Hansen’s Hospital, Sandvika, Norway. 1775. The ACR/EULAR 2010 Criteria as Well as Other Predictive Algorithms for Rheumatoid Arthritis Show Good Diagnostic Performance. Celina Alves 2 , Jolanda Luime 1 , Jendé van Zeben 4 , Margriet Huisman 4 , Angelique Weel 3 , Pieternella Barendregt 3 and Johanna Hazes 1 , 1 Erasmus MC, 2 Erasmus MC, Rotterdam, The Netherlands, 3 Maasstad Ziekenhuis, 4 Sint Franciscus Gasthuis. 1776. The Diagnostic Performance of the ACR/EULAR 2010 Criteria If One of Its Parameters Is Not Available. Results from the Rotterdam Early Arthritis CoHort (REACH). Celina Alves 2 , Jolanda Luime 1 , Jendé van Zeben 4 , Margriet Huisman 4 , Angelique Weel 3 , Pieternella Barendregt 3 and Johanna Hazes 1 , 1 Erasmus MC, 2 Erasmus MC, Rotterdam, The Netherlands, 3 Maasstad Ziekenhuis, 4 Sint Franciscus Gasthuis. 1777. The Performance of the Hospital Anxiety and Depression Scale for Screening of Depressive and Anxiety Disorders in Patients with Rheumatoid Arthritis (RA). Eugenia Y. C. Lok 1 , Chi Chiu Mok 2 , Fuk Chi Cheung 1 and Chi Wai Cheng 1 , 1 Castle Peak Hospital, 2 Tuen Mun Hospital. 1778. The Role of Objective Measures vs. Patient Reported Outcomes (PROs) as a Reflection of Flares in Patients with RA: Results from the Brigham RA Sequential Study (BRASS). Vivian Bykerk 1 , Daniel Hal Solomon 5 , Clifton O. Bingham 6 , Michelle Frits 3 , Christine Iannaccone 4 , Michael E. Weinblatt 5 and Nancy A. Shadick 5 , 1 Brigham &Women’s Hospital, Boston, MA, 2 Brigham and Women’s Hospital, Jamaica Plain, MA, 3 Brigham and Women’s Hospital, Boston, MA, 4 Brigham and Women’s Hospital, MA, 5 Brigham and Womens Hospital, Boston, MA, 6 Johns Hopkins University, Baltimore, MD. 1779. Total MRI Inflammatory Score Correlates with Disease Activity Measures after Aggressive Treatment of Rheumatoid Arthritis. Veena K. Ranganath 3 , David A. Elashoff 4 , Paul Maranian 4 , Kambiz Motamedi 4 , Espen Haavardsholm 2 , Fiona M. McQueen 5 , Theresa McVie 7 , Stacey S. Cofield 7 , Larry W. Moreland 6 , Weiling Chen 4 and Harold E. Paulus 1 , 1 Encino, CA, 2 Diakonhjemmet Hospital, 3 UCLA, Los Angeles, CA, 4 UCLA, 5 Univ of Auckland Sch of Med, Auckland, New Zealand, 6 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 7 University of Birmingham.
ACR/ARHP Poster Session C 1780. Towards a Data-Driven Evaluation of the 2010 ACR/EULAR Criteria for Rheumatoid Arthritis: Is It Sensible To Look at Levels of Rheumatoid Factor? M. P. M. van der Linden 4 , M. R. Batstra 1 , L. E. Bakker-Jonges 1 , J. Detert 2 , H. Bastian 2 , H. U. Scherer 2 , G. R. Burmester 2 , M. D. Mjaavatten 3 , T. K. Kvien 3 , R. E. M. Toes 4 , T. W. J. Huizinga 4 and A. H. M. van der Helm-van Mil 4 , 1 Department of Medical Laboratories, Reinier de Graaf Group, Delft, The Netherlands, on Behalf of SKML-HIM (WGHAS), 2 Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, 3 Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. 1781. Ultrasound Evaluation Reveals the Reason for High Interrater Variability in Joints of the 66/68 Joint Count. Matthias Nikolaus Witt 2 , Monika Ronneberger 1 , Amelie Schnez 3 , Ruediger Laubender 4 , Matthias Engelbrecht 1 , Arthur Kavanaugh 6 , Hendrik Schulze-Koops 5 and Mathias Grunke 3 , 1 Department of Internal Medicine 3 , University of Erlangen-Nuremberg, Erlangen, Germany, 2 Division of Rheumatology, Ludwig-Maximilians- University, Munich, Germany, 3 Division of Rheumatology, Ludwig-Maximilians-University, Munich, Germany, 4 Institute of Medical Informatics, Biometry and Epidemiology (IBE), Ludwig- Maximilians-University, Munich, Germany, 5 Ludwig-Maximilians- University, Munich, Germany, 6 University of California-San Diego, La Jolla, CA. 1782. Validation of a Multi-Biomarker Test for Rheumatoid Arthritis (RA) Disease Activity (Vectra DA) in a Multi-Cohort Study. Jeffrey R. Curtis 9 , Doug Haney 3 , Annette H. M. van der Helm 5 , Yijing Shen 3 , Rachel Knevel 5 , Guy Cavet 3 , Linda Dirven 5 , Cornelia F. Allaart 4 , Thomas W. J. Huizinga 5 , Michael Centola 6 , Lyndal K. Hesterberg 3 , David Chernoff 3 , John Carulli 1 , Nancy A. Shadick 2 , Michael E. Weinblatt 2 , Max I. Hamburger 8 , Roy M. Fleischmann 7 and Ed C. Keystone 10 , 1 Biogen Idec, 2 Brigham &Womens Hospital, Boston, MA, 3 Crescendo Bioscience, Inc., 4 Leiden Univ Med Ctr, Leiden, The Netherlands, 5 Leiden Univ Med Ctr, 6 Oklahoma Med Research Foundation, Oklahoma City, OK, 7 Rheumatology Associates, Dallas, TX, 8 Rheumatology Associates of LI, Dix Hills, NY, 9 University of Alabama - Brimingham, Birmingham, AL, 10 University of Toronto, Toronto, ON, Canada. 1783. Validation of New Classification Criteria for Rheumatoid Arthritis in Japanese Population. Hisanori Shimizu 1 , Hiromichi Tamaki 3 , Eishi Uechi 3 , Mitsumasa Kishimoto 2 , Ken-ichi Yamaguchi 3 and Masato Okada 1 , 1 St. Luke’s International Hospital, Tokyo, Japan, 2 St. Luke’s International Hospital, Chuoku, Tokyo, Japan, 3 St. Luke’s International Hospital. 1784. Validity of Clinical Associations of Biomarkers in Translational Research Studies: The Case of Systemic Autoimmune Diseases. Maria Tektonidou 2 and Michael Ward 1 , 1 National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2 National University of Athens. 1785. Validity of the Revised ACR/EULAR Classification Criteria for Rheumatoid Arthritis: Predicting Persistent Arthritis and Joint Erosions after 2 Years in Patients with Early Undifferentiated Arthritis. Jaap Fransen 3 , Mieke Hazes 2 and Henk Visser 1 , 1 Alysis Hospital, Arnhem, The Netherlands, 2 Erasmus Medical Centre, Rotterdam, The Netherlands, 3 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 1786. Vitamin D Levels Do Not Correlate with Disease Activity, Erosions, or Inflammatory Markers in Patients with Active Rheumatoid Arthritis. Joshua Baker 2 , Daniel G. Baker 1 , Gary Toedter, Justine Shults and Mary B. Leonard, 1 Centocor Inc, Malvern, PA, 2 University of Pennsylvania, Philadelphia, PA. 1787. Work Disability in Early Rheumatoid Arthritis: Prognostic Factors after Two Years of Follow-Up. Fausto Salaffi 1 , Gianfranco Ferraccioli 3 , Marina Carotti 2 , Alessandro Ciapetti 1 , Stefania Gasparini 1 and Walter Grassi 1 , 1 Department of Molecular Pathology and Innovative Therapies, Division of Rheumatology, University of Ancona (Politecnica delle Marche), Italy, 2 Department of Radiology, University of Ancona (Politecnica delle Marche), Italy, 3 School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Biologic DMARDs III 1788. A Study To Evaluate the Effectiveness and Safety of the Interleukin-6 (IL-6) Receptor Antagonist Tocilizumab (TCZ) after 4 and 24 Weeks in Patients with Active Rheumatoid Arthritis (RA) – Final Effectiveness Results of the TAMARA Study. Eugen Feist 1 , Andrea Rubbert-Roth 2 , Jürgen Braun 6 , Jörg Kaufmann 4 , Herbert L. Kellner 7 , Reiner Kurthen 3 , Jürgen Wollenhaupt 5 and Gerd R. Burmester 1 , 1 Campus Charité Mitte, Med. Klinik Abt. Rheumatologie u. Klin. Immunologie, Berlin, Germany, 2 Klinik I für Innere Medizin, Uniklinik Cologne, Cologne, Germany, 3 Praxis für Innere Medizin und Rheumatologie, Aachen, Germany, 4 Praxis für Innere Medizin und Rheumatologie, Ludwigsfelde, Germany, 5 Rheumatologikum Hamburg, Schön-Klinik Hamburg- Eilbeck, Hamburg, Germany, 6 Rheumazentrum Ruhrgebiet, St. Josefs-Krankenhaus, Herne, Germany, 7 Schwerpunktpraxis fuer Rheumatologie und Gastroenterologie, Munich, Germany. 1789. Age at Onset and Comorbidities Correlate with the Health Assessment Questionnaire and Clinical Disease Activity Index (CDAI) Responses to Etanercept in Rheumatoid Arthritis Patients. Man R. Shim 6 , Harold E. Paulus 1 , Sandeep Chaudhari 3 , JingYaun Feng 2 , David A. Elashoff 4 and Veena K. Ranganath 5 , 1 Encino, CA, 2 Amgen, 3 Kforce Clinical Research/Amgen, 4 UCLA, 5 UCLA School of Med Rehab 32-59, Los Angeles, CA, 6 UCLA/ VA Greater Los Angeles Healthcare System, Los Angeles, CA. 1790. Assessment of Real Life Efficacy of Rituximab in Rheumatoid Arthritis: Predicting Factors of the Therapeutic Maintenance and Demonstration of a Corticosteroid Sparing Effect in the AutoImmunity and Rituximab Registry. Jacques-Eric Gottenberg 10 , Philippe Ravaud 4 , Thomas Bardin 6 , Patrice Cacoub 5 , Alain Cantagrel 11 , Bernard Combe 8 , Maxime Dougados 2 , René-Marc Flipo 7 , Bertrand Godeau 3 , Loic Guillevin 2 , Eric Hachulla 7 , Xavier Le Loët 9 , Thierry Schaeverbeke 1 , Jean Sibilia 10 , Gabriel Baron 4 and Xavier Mariette, 1 Bordeaux Hospital, 2 Cochin Hospital, 3 Henri Mondor Hospital, 4 Hotel Dieu Hospital, 5 La Pitié Hospital, 6 Lariboisière Hospital, 7 Lille Hospital, 8 Montpellier Hospital, 9 Rouen Hospital, 10 Strasbourg Hospital, 11 Toulouse Hospital. 1791. Clinical and Functional Improvements in Early RA Following Treatment with Adalimumab Plus Methotrexate Compared with Methotrexate Monotherapy: 26-Week Results of the OPTIMA Trial. Arthur Kavanaugh 5 , Roy Fleischmann 6 , Paul Emery 3 , Benoit Guérette 1 , Laura Redden 2 , Kaushik Patra 2 and Josef S. Smolen 4 , 1 Abbott Laboratories, Rungis, France, 2 Abbott Laboratories, Abbott Park, IL, 3 Leeds Teaching Hospital, Leeds, United Kingdom, 4 Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 5 University of California San Diego, La Jolla, CA, 6 University of Texas Southwestern Medical Center, Dallas, TX. 2010 Program Book 257
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
Page 123 and 124:
Session Overview: We are witnessing
Page 125 and 126:
Session Overview: Systemic sclerosi
Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
Page 131 and 132:
4:30 PM 2198. Association between V
Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138:
• apply these basic statistics to
Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
Page 141 and 142:
Immunology, Oslo University Hospita
Page 143 and 144:
9:15 AM 2239. Factors Associated wi
Page 145 and 146:
Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
Page 151 and 152:
ACR Poster Session A Cytokines, Med
Page 153 and 154:
ACR Poster Session A 51. Associatio
Page 155 and 156:
ACR Poster Session A 83. Respirator
Page 157 and 158:
ACR Poster Session A 121. Bone Dens
Page 159 and 160:
ACR Poster Session A 142. The Intra
Page 161 and 162:
ACR Poster Session A 171. Early Pro
Page 163 and 164:
ACR Poster Session A Pediatric Rheu
Page 165 and 166:
ACR Poster Session A 233. Prevalenc
Page 167 and 168:
ACR Poster Session A 266. Subtype S
Page 169 and 170:
ACR Poster Session A 297. Body Weig
Page 171 and 172:
ACR Poster Session A 325. Patient R
Page 173 and 174:
ACR Poster Session A 356. Influence
Page 175 and 176:
ACR Poster Session A 383. Efficacy
Page 177 and 178:
ACR Poster Session A 409. Rituximab
Page 179 and 180:
ACR Poster Session A 441. Recombina
Page 181 and 182:
ACR Poster Session A 465. Immunoglo
Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
Page 187 and 188:
ACR Poster Session A 546. Prevalenc
Page 189 and 190:
ACR Poster Session A 571. Epidemiol
Page 191 and 192:
ACR Poster Session A 599. Validatio
Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
Page 195 and 196:
ACR Poster Session B 767. Economic
Page 197 and 198:
ACR/ARHP Poster Session B 792. The
Page 199 and 200:
ACR/ARHP Poster Session B Universit
Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
Page 207 and 208: ACR/ARHP Poster Session B 935. The
Page 209 and 210: ACR/ARHP Poster Session B 967. Frac
Page 211 and 212: ACR Poster Session B 993. Early Exp
Page 213 and 214: ACR/ARHP Poster Session B 1022. Com
Page 215 and 216: ACR/ARHP Poster Session B 1055. Son
Page 217 and 218: ACR Poster Session B 1084. Gene Exp
Page 219 and 220: ACR/ARHP Poster Session B 1111. Inc
Page 221 and 222: ACR Poster Session B hiroshima Memo
Page 223 and 224: ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226: ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228: ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230: ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232: ACR/ARHP Poster Session B 1294. End
Page 233 and 234: ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236: ACR/ARHP Poster Session C Halls B1
Page 237 and 238: ACR/ARHP Poster Session C 1495. S10
Page 239 and 240: ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242: ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244: ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246: ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248: ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250: ACR/ARHP Poster Session C Miscellan
Page 251 and 252: ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254: ACR/ARHP Poster Session C 1692. Res
Page 255 and 256: ACR/ARHP Poster Session C 1719. Los
Page 257: ACR/ARHP Poster Session C 1749. Con
Page 261 and 262: ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264: ACR/ARHP Poster Session C Immunolog
Page 265 and 266: ACR/ARHP Poster Session C 2 Departm
Page 267 and 268: ACR/ARHP Poster Session C CA, 29 Un
Page 269 and 270: ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272: ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274: ACR/ARHP Poster Session C 1958. The
Page 275 and 276: ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278: ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280: ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282: ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284: REF Industry Roundtable-supported S
Page 285 and 286: REF Industry Roundtable-supported S
Page 287 and 288: INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290: 2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292: 2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294: FLOOR PLANS 2010 Program Book 291
Page 295 and 296: VISIT THE EXHIBIT HALL New and inno
Page 297 and 298: EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300: ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302: ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304: A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306: Cooper, Max D, MD Introduction . .
Page 307 and 308: Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310:
Physical Examination Skills for Imp
Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326:
Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328:
Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330:
Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332:
Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334:
Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336:
Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338:
Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340:
Looney, C 941 Looney, MR 609 Looney
Page 341 and 342:
McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344:
Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346:
Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348:
Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350:
Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352:
1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354:
Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356:
636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358:
Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360:
A α-galactosylceramide 505 A2A kno
Page 361 and 362:
Behcet’s syndrome 1284, 1288, 129
Page 363 and 364:
cost-utility 759, 1539 couples 1324
Page 365 and 366:
fibroblast like synoviocyte 27 fibr
Page 367 and 368:
impact 1063, 1325 inactive disease
Page 369 and 370:
methylation 826, 1253, 1489 methylt
Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
Page 377 and 378:
Abelson, Abby Goulder, MD Education
Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
Page 381 and 382:
ACR Annual Meeting fellowS-in-train
Page 383 and 384:
NOTES 2010 Program Book 381
Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
Page 387 and 388:
Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?